+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Lyme Disease Diagnostics Market Report and Forecast 2023-2031

  • PDF Icon


  • 180 Pages
  • July 2023
  • Region: Global
  • Expert Market Research
  • ID: 5855139
The global Lyme disease diagnostics market attained a value of USD 2.5 billion in 2022, driven by the rising prevalence of Lyme disease and the emergence of new Lyme diagnostic tests. The market is expected to grow at a CAGR of 6.86% during the forecast period of 2023-2031 to attain a value of USD 4.5 billion by 2031.

Lyme Disease Diagnostics: Introduction

Lyme disease diagnostics refers to the methods and tests used to detect and confirm the presence of Lyme disease, a tick-borne illness caused by the bacteria Borrelia burgdorferi. Diagnostic tools help healthcare professionals identify and diagnose Lyme disease, allowing for appropriate treatment and management.

The uses of Lyme disease diagnostics include:

  • Early Detection: Prompt and accurate diagnosis of Lyme disease is crucial for initiating timely treatment. Diagnostic tests enable healthcare providers to identify the presence of Lyme disease in individuals who exhibit symptoms or have been exposed to tick bites. Early detection allows for early intervention, reducing the risk of complications and long-term health effects associated with untreated Lyme disease
  • Confirmation of Infection: Lyme disease diagnostics help confirm the presence of the Borrelia burgdorferi bacteria in the body. This is particularly important because Lyme disease shares symptoms with other conditions, and a definitive diagnosis ensures appropriate treatment is provided
  • Differential Diagnosis: Lyme disease diagnostics assist in distinguishing Lyme disease from other illnesses with similar symptoms, such as flu-like symptoms or other tick-borne diseases. Accurate diagnosis helps healthcare professionals rule out other potential causes and focus on appropriate treatment strategies
  • Monitoring Treatment Efficacy: Diagnostic tests can be used to assess the effectiveness of Lyme disease treatment over time. By monitoring antibody levels or the presence of the bacteria, healthcare providers can determine if the treatment is successfully eliminating the infection or if further interventions are necessary

The benefits of Lyme disease diagnostics include:

  • Accurate Diagnosis: Diagnostic tests for Lyme disease provide a reliable means of confirming or ruling out the presence of the bacteria causing the disease. Accurate diagnosis leads to appropriate treatment and management, ensuring patients receive the necessary care
  • Early Treatment: Early diagnosis through effective diagnostics allows for timely treatment initiation. Early treatment is essential in preventing the progression of Lyme disease and reducing the risk of complications, such as chronic symptoms or long-term health issues
  • Targeted Therapy: Lyme disease diagnostics help healthcare professionals select the appropriate treatment strategy based on the severity of the infection. Targeted therapy ensures that patients receive the most effective medications and interventions for managing their specific case of Lyme disease
  • Peace of Mind: For individuals who suspect they may have been exposed to ticks or exhibit symptoms suggestive of Lyme disease, diagnostic tests provide peace of mind by confirming or ruling out the presence of the bacteria. This clarity helps alleviate anxiety and guides appropriate healthcare decisions
  • Public Health Monitoring: Lyme disease diagnostics contribute to public health surveillance efforts by providing data on the prevalence and distribution of Lyme disease. This information assists in tracking the spread of the disease, identifying high-risk areas, and implementing preventive measures
It is important to note that Lyme disease diagnostics may include a combination of methods, such as serological tests (detecting antibodies), polymerase chain reaction (PCR) tests (detecting bacterial DNA), and clinical evaluations. The selection and interpretation of diagnostic tests should be performed by qualified healthcare professionals experienced in managing Lyme disease.

Lyme Disease Diagnostics Market Segmentations

The market can be categorised into diagnostic technology, end user, and region.

Market Breakup by Diagnostic Technology

Serological Test

  • Western Blot
  • Lymphocytic Transformation Test
  • Urine Antigen Testing
  • Immunofluorescent Staining
  • Nucleic acid Test

Market Breakup by End User

  • Hospitals
  • Clinical Laboratories
  • Other
Lyme Disease Diagnostics Market Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

Lyme Disease Diagnostics Market Overview

The Lyme disease diagnostics market has witnessed significant growth and is expected to continue expanding in the coming years. Several factors contribute to the positive market scenario.

One of the primary drivers of market growth is the increasing incidence of Lyme disease worldwide. The prevalence of Lyme disease has been on the rise, particularly in regions where ticks carrying the Borrelia burgdorferi bacteria are abundant. This has resulted in a greater demand for accurate and reliable diagnostic tools to detect and confirm Lyme disease infections.

Furthermore, advancements in diagnostic technologies have expanded the capabilities and accuracy of Lyme disease diagnostics. Serological tests, such as enzyme immunoassays (EIAs) and Western blot tests, are commonly used to detect antibodies produced in response to the Borrelia burgdorferi bacteria. Additionally, molecular diagnostic methods such as polymerase chain reaction (PCR) and nucleic acid amplification tests (NAATs) are increasingly employed for the direct detection of the bacteria's genetic material. These technological advancements have improved the sensitivity, specificity, and turnaround time of Lyme disease diagnostic tests, enhancing their clinical utility.

In conclusion, the Lyme disease diagnostics market is expected to witness significant growth due to the increasing incidence of Lyme disease, growing awareness, advancements in diagnostic technologies, and public health initiatives. As the demand for accurate and timely diagnosis of Lyme disease continues to rise, there will be a focus on developing more sensitive and specific diagnostic tools and improving testing protocols. Continued investment in research and development, quality assurance, and effective implementation strategies will shape the future of the Lyme disease diagnostics market.

Key players in the global lyme disease diagnostics market

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the Lyme disease diagnostics market are as follows:
  • Abbott Laboratories
  • Bio-Rad Laboratories
  • Covance Inc
  • Fres F. Hoffmann-La Roche AG
  • T2 Biosystems
  • Oxford Immunotec
  • Baxter
  • Fresenius Medical Care
  • Bolder Biotechnology, Inc
  • Roche Holding AG
  • Siemens AG
  • Immunetics Inc
  • GlaxoSmithKline Pharmaceuticals
  • Canon Lifesciences
  • Covance
*The publisher always strives to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Lyme Disease Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Lyme Disease Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Lyme Disease Epidemiology (2016-2031)
5.3 Europe Lyme Disease Epidemiology (2016-2031)
5.4 Asia-Pacific Lyme Disease Epidemiology (2016-2031)
5.5 Latin America Lyme Disease Epidemiology (2016-2031)
5.6 Middle East & Africa Lyme Disease Epidemiology (2016-2031)
6 Global Lyme Disease Diagnostic Market Overview
6.1 Global Lyme Disease Diagnostic Market Historical Value (2016-2022)
6.2 Global Lyme Disease Diagnostic Market Forecast Value (2023-2031)
7 Lyme Disease Diagnostic Challenges and Unmet Needs
7.1 Treatment Pathway Challenges
7.2 Compliance and Drop-Out Analysis
7.3 Awareness and Prevention Gaps
8 Cost of Treatment
9 Global Lyme Disease Diagnostic Market Dynamics
9.1 Market Drivers and Constraints
9.2 SWOT Analysis
9.3 Porter’s Five Forces Model
9.4 Key Demand Indicators
9.5 Key Price Indicators
9.6 Industry Events, Initiatives, and Trends
9.7 Value Chain Analysis
10 Global Lyme Disease Diagnostic Market Segmentation
10.1 Global Lyme Disease Diagnostic Market by Diagnostic Technology
10.1.1 Market Overview
10.1.2 Serological Test Elisa Western Blot Others
10.1.3 Lymphocytic Transformation Test
10.1.4 Urine Antigen Testing
10.1.5 Immunofluorescent Staining
10.1.6 Nucleic Acid Test
10.2 Global Lyme Disease Diagnostic Market by End User
10.2.1 Market Overview
10.2.2 Hospitals
10.2.3 Clinics
10.2.4 Diagnostic Laboratories
10.3 Global Lyme Disease Diagnostic Market by Region
10.3.1 Market Overview
10.3.2 North America
10.3.3 Europe
10.3.4 Asia Pacific
10.3.5 Latin America
10.3.6 Middle East and Africa
11 North America Lyme Disease Diagnostic Market
11.1 Market Share by Country
11.2 United States of America
11.3 Canada
12 Europe Lyme Disease Diagnostic Market
12.1 Market Share by Country
12.2 United Kingdom
12.3 Germany
12.4 France
12.5 Italy
12.6 Others
13 Asia Pacific Lyme Disease Diagnostic Market
13.1 Market Share by Country
13.2 China
13.3 Japan
13.4 India
13.5 ASEAN
13.6 Australia
13.7 Others
14 Latin America Lyme Disease Diagnostic Market
14.1 Market Share by Country
14.2 Brazil
14.3 Argentina
14.4 Mexico
14.5 Others
15 Middle East and Africa Lyme Disease Diagnostic Market
15.1 Market Share by Country
15.2 Saudi Arabia
15.3 United Arab Emirates
15.4 Nigeria
15.5 South Africa
15.6 Others
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.5 Others
17 Patent Analysis
17.1 Analysis by Type of Patent
17.2 Analysis by Publication year
17.3 Analysis by Issuing Authority
17.4 Analysis by Patent Age
17.5 Analysis by CPC Analysis
17.6 Analysis by Patent Valuation
17.7 Analysis by Key Players
18 Grants Analysis
18.1 Analysis by year
18.2 Analysis by Amount Awarded
18.3 Analysis by Issuing Authority
18.4 Analysis by Grant Application
18.5 Analysis by Funding Institute
18.6 Analysis by NIH Departments
18.7 Analysis by Recipient Organization
19 Clinical Trials Analysis
19.1 Analysis by Trial Registration Year
19.2 Analysis by Trial Status
19.3 Analysis by Trial Phase
19.4 Analysis by Therapeutic Area
19.5 Analysis by Geography
20 Funding and Investment Analysis
20.1 Analysis by Funding Instances
20.2 Analysis by Type of Funding
20.3 Analysis by Funding Amount
20.4 Analysis by Leading Players
20.5 Analysis by Leading Investors
20.6 Analysis by Geography
21 Partnership and Collaborations Analysis
21.1 Analysis by Partnership Instances
21.2 Analysis by Type of Partnership
21.3 Analysis by Leading Players
21.4 Analysis by Geography
22 Supplier Landscape
22.1 T2 Biosystems, Inc.
22.1.1 Financial Analysis
22.1.2 Product Portfolio
22.1.3 Demographic Reach and Achievements
22.1.4 Mergers and Acquisitions
22.1.5 Certifications
22.2.1 Financial Analysis
22.2.2 Product Portfolio
22.2.3 Demographic Reach and Achievements
22.2.4 Mergers and Acquisitions
22.2.5 Certifications
22.3 DiaSorin S.p.A.
22.3.1 Financial Analysis
22.3.2 Product Portfolio
22.3.3 Demographic Reach and Achievements
22.3.4 Mergers and Acquisitions
22.3.5 Certifications
22.4 Bio-Rad Laboratories
22.4.1 Financial Analysis
22.4.2 Product Portfolio
22.4.3 Demographic Reach and Achievements
22.4.4 Mergers and Acquisitions
22.4.5 Certifications
22.5 Thermo Fisher Scientific, Inc.
22.5.1 Financial Analysis
22.5.2 Product Portfolio
22.5.3 Demographic Reach and Achievements
22.5.4 Mergers and Acquisitions
22.5.5 Certifications
22.6 Trinity Biotech plc
22.6.1 Financial Analysis
22.6.2 Product Portfolio
22.6.3 Demographic Reach and Achievements
22.6.4 Mergers and Acquisitions
22.6.5 Certifications
22.7 IGeneX, Inc.
22.7.1 Financial Analysis
22.7.2 Product Portfolio
22.7.3 Demographic Reach and Achievements
22.7.4 Mergers and Acquisitions
22.7.5 Certifications
22.8 Lyme Diagnostics Ltd.
22.8.1 Financial Analysis
22.8.2 Product Portfolio
22.8.3 Demographic Reach and Achievements
22.8.4 Mergers and Acquisitions
22.8.5 Certifications
22.9 PerkinElmer, Inc.
22.9.1 Financial Analysis
22.9.2 Product Portfolio
22.9.3 Demographic Reach and Achievements
22.9.4 Mergers and Acquisitions
22.9.5 Certifications
22.10 Cenogenics Corporation
22.10.1 Financial Analysis
22.10.2 Product Portfolio
22.10.3 Demographic Reach and Achievements
22.10.4 Mergers and Acquisitions
22.10.5 Certifications
22.11 Quest Diagnostics
22.11.1 Financial Analysis
22.11.2 Product Portfolio
22.11.3 Demographic Reach and Achievements
22.11.4 Mergers and Acquisitions
22.11.5 Certifications
22.12 Ceres Nanosciences, Inc.
22.12.1 Financial Analysis
22.12.2 Product Portfolio
22.12.3 Demographic Reach and Achievements
22.12.4 Mergers and Acquisitions
22.12.5 Certifications
22.13 Galaxy Diagnostics
22.13.1 Financial Analysis
22.13.2 Product Portfolio
22.13.3 Demographic Reach and Achievements
22.13.4 Mergers and Acquisitions
22.13.5 Certifications
22.14 Abbott
22.14.1 Financial Analysis
22.14.2 Product Portfolio
22.14.3 Demographic Reach and Achievements
22.14.4 Mergers and Acquisitions
22.14.5 Certifications
23 Lyme Disease Diagnostic - Distribution Model (Additional Insight)
23.1 Overview
23.2 Potential Distributors
23.3 Key Parameters for Distribution Partner Assessment
24 Key Opinion Leaders (KOL) Insights (Additional Insight)
25 Company Competitiveness Analysis (Additional Insight)
25.1 Very Small Companies
25.2 Small Companies
25.3 Mid-Sized Companies
25.4 Large Companies
25.5 Very Large Companies
26 Payment Methods (Additional Insight)
26.1 Government Funded
26.2 Private Insurance
26.3 Out-of-Pocket
  • *Additional insights provided are customisable as per client requirements.

Companies Mentioned

  • Abbott Laboratories
  • Bio-Rad Laboratories
  • Covance Inc.
  • Fres F. Hoffmann-La Roche AG
  • T2 Biosystems
  • Oxford Immunotec
  • Baxter
  • Fresenius Medical Care
  • Bolder Biotechnology, Inc.
  • Roche Holding AG
  • Siemens AG
  • Immunetics Inc
  • GlaxoSmithKline Pharmaceuticals
  • Canon Lifesciences
  • Covance



Table Information